June 2021
Strong launch for our hepatitis B discrimination registry
People globally who are living with hepatitis B often experience discrimination in a variety of ways, including denial of access to employment and education, even in the United States, and we recently launched the world’s first initiative to track and analyze that discrimination.

Our Discrimination Registry has gotten off to a strong start, with more than 57 completed responses from countries around the world, including Ghana, China, Australia and the U.S. You can use the information on our site to help advocate for yourself, report your experience with discrimination on the Hepatitis B Foundation's Discrimination Registry or contact the Hepatitis B Foundation at discrimination@hepb.org or 215-489-4900 if you need additional assistance.

The impact of COVID-19 on people living with hepatitis B
Kate Moraras, MPH, the Hepatitis B Foundation's deputy director of public health, recently wrote a guest blog for the National Foundation for Infectious Diseases highlighting the impact of the COVID-19 pandemic on people with hepatitis B in the U.S.

Many have faced increased challenges in accessing medical care and treatment due to delayed appointments and deprioritization of routine hepatitis or primary care services, according to Ms. Moraras.

Not only have patients had to adjust to telemedicine, but they also experienced difficulty getting antiviral refills and disruptions in mail-order delivery.

Others have had trouble navigating specific health information related to COVID-19 for people with liver disease and concerns related to the safety and efficacy of COVID-19 vaccines for people living with hepatitis B and liver disease. Please read more here.
Preventing HIV and hepatitis B co-infection
June is Pride Month in the United States and the Hepatitis B Foundation is celebrating the LGBTQ+ community.

A new posting on our blog discusses HIV/HBV co-infection in LGBTQ+ individuals and how to prevent both viruses.

You can find our blog here.
Announcing New Liver Cancer Clinical Trials
The pharmaceutical company Bristol Myers Squibb is now enrolling for two clinical trials in liver cancer (also called hepatocellular carcinoma or HCC). The reference numbers for these trials are CA209-9DW and CA209-74W.

If you're eligible and willing and able to take part, you'll be helping to advance research. Eligible participants must be at least age 18 years old and diagnosed with liver cancer. These two trials are researching the safety and efficacy of new study drugs compared to a standard of care (CA209-74W) and to other standard drugs (CA209-9DW).

Click here to learn more about full trial requirements, lists of tests and procedures used to determine trial eligibility and more details about clinical trial participation in general.
World Hepatitis Day podcast to feature HepBcommunity.org
"B Heppy" is the name of our brand-new podcast series and the World Hepatitis Day (July 28) edition will feature Thomas Tu, PhD, founder of HepBcommunity.org, a new global online forum dedicated to supporting those living with and affected by hep B.

Previous episodes include interviews with Joan Block and Jan Witte, two of our founders, talking about our organization's 30-year history. We also have Dr. Chari Cohen's excellent Hep B 101 presentation, which is highly educational and understandable. You can find the podcast here.
Congratulations to all of this year’s graduates!
Support Blumberg education programs-
to join our Champions Club, click here!
Health care providers: Upcoming complimentary CME workshop!
Join experts Robert Gish, MD, Hepatitis B Foundation medical director, and Aekata Shah, DO, in a one-hour, complimentary, accredited CME virtual workshop. You'll hear recommendations for hepatitis B virus (HBV) testing, best practices for patient education and counseling, treatment considerations for patients with chronic HBV and hepatocellular carcinoma (HCC) risk, screening and surveillance. Patient advocates also will discuss perspectives from the patient community on the challenges they face regarding HBV testing and treatment. Space is limited. Reserve your spot today! More details here.
Hepatitis B Foundation's journal pick of the month
Common concerns, barriers to care and the lived experience of individuals with hepatitis B: a qualitative study
Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Block T, Frasso R, Cohen C
BMS Public Health  May 28, 2021
Though about 300 million people around the world are living with hepatitis B, very little is know about the quality of life and impact of HBV on those living with the infection. This study reviewed a random sample of HBV-related email queries sent to the Hepatitis B Foundation during a one-year period in 2018-19. The contenst were analyzed qualitatively to highlight information needs and explore the experiences of people living with HBV and their families and loved ones. The analysis revealed three themes: 1) health-specific challenges, 2) emotional needs and 3) informational needs related to prevention and transmission, and interpretation of lab tests. You can access the article here.
Free research seminar series continues online
The Baruch S. Blumberg Institute, which is our research arm, has a strong lineup of prominent scientists in hepatitis B and liver diseases for its online Distinguished Speaker Seminars. The series is free-of-charge and open to anyone interested (pre-registration is required).

On June 17 at 11 a.m. EDT, Maura Dandri, PhD, University of Hamburg, Germany, will speak about "cccDNA shut down in chronic hepatitis B."

Dr. Maura Dandri

On July 22 at 11 a.m. EDT, Philip S. Low, PhD, will discuss "Targeted Immunotherapies for Viral Diseases.” The registration link will be available shortly.

Upcoming seminars are listed on the Institute's website here, where you also can watch recordings of prior Blumberg 2020 Research Seminars.
Get an insider's look at our Annual Report
Our leadership team gave a detailed overview of our 2020 Annual Report during a webinar on June 8, which we recorded. Hosted by Jean Holmes, MBA, vice president, institutional advancement, the webinar included presentations by Timothy Block, PhD, president; Ju-Tao Guo, MD, Blumberg Institute vice president; and Chari Cohen, DrPH, MPH, senior vice president, public health. The recording is posted here.
Patients are invited to join us for a patient forum this fall
A patient forum, hosted by the Hepatitis B Foundation, is set for Sept. 30 during the HBV International meeting. The forum will facilitate engaging conversations among hepatitis B communities, particularly patients and the doctors, nurses, public health professionals and scientists participating in the influential International HBV Meeting. The goal is to fast-track an HBV cure and to eliminate stigma and discrimination. More info is here.
July 28
World Hepatitis Day
Details pending

Sept. 26-30
International HBV Meeting on the
Molecular Biology of Hepatitis B Viruses
Toronto

Nov. 2-4
Hep B United Summit
Details pending

Nov. 4
Regional Biotechnology Conference
Pennsylvania Biotechnology Center
Doylestown, Pa.
Details pending
Learn more about our research and education programs at www.hepb.org
The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community, and the general public.
Hepatitis B Foundation I 3805 Old Easton Road Doylestown, PA 18902 I
215-489-4900 I info@hepb.org